JP2023546362A5 - - Google Patents

Info

Publication number
JP2023546362A5
JP2023546362A5 JP2023521357A JP2023521357A JP2023546362A5 JP 2023546362 A5 JP2023546362 A5 JP 2023546362A5 JP 2023521357 A JP2023521357 A JP 2023521357A JP 2023521357 A JP2023521357 A JP 2023521357A JP 2023546362 A5 JP2023546362 A5 JP 2023546362A5
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
cancer
acceptable salt
pharmaceutical
chemotherapeutic agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2023521357A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023546362A (ja
JP7818585B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2021/077703 external-priority patent/WO2022074124A1/en
Publication of JP2023546362A publication Critical patent/JP2023546362A/ja
Publication of JP2023546362A5 publication Critical patent/JP2023546362A5/ja
Application granted granted Critical
Publication of JP7818585B2 publication Critical patent/JP7818585B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2023521357A 2020-10-08 2021-10-07 癌を治療するための組み合わせ療法 Active JP7818585B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063089195P 2020-10-08 2020-10-08
US63/089,195 2020-10-08
PCT/EP2021/077703 WO2022074124A1 (en) 2020-10-08 2021-10-07 Combination therapy for treating cancer

Publications (3)

Publication Number Publication Date
JP2023546362A JP2023546362A (ja) 2023-11-02
JP2023546362A5 true JP2023546362A5 (cg-RX-API-DMAC7.html) 2024-09-20
JP7818585B2 JP7818585B2 (ja) 2026-02-20

Family

ID=78293953

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023521357A Active JP7818585B2 (ja) 2020-10-08 2021-10-07 癌を治療するための組み合わせ療法

Country Status (19)

Country Link
US (1) US20230372333A1 (cg-RX-API-DMAC7.html)
EP (1) EP4225297B1 (cg-RX-API-DMAC7.html)
JP (1) JP7818585B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230083291A (cg-RX-API-DMAC7.html)
CN (1) CN116194110B (cg-RX-API-DMAC7.html)
AU (1) AU2021356123B2 (cg-RX-API-DMAC7.html)
BR (1) BR112023005160A2 (cg-RX-API-DMAC7.html)
CA (1) CA3197056A1 (cg-RX-API-DMAC7.html)
DK (1) DK4225297T3 (cg-RX-API-DMAC7.html)
ES (1) ES3005507T3 (cg-RX-API-DMAC7.html)
FI (1) FI4225297T3 (cg-RX-API-DMAC7.html)
HU (1) HUE069249T2 (cg-RX-API-DMAC7.html)
IL (1) IL301687A (cg-RX-API-DMAC7.html)
MX (1) MX2023004156A (cg-RX-API-DMAC7.html)
PL (1) PL4225297T3 (cg-RX-API-DMAC7.html)
PT (1) PT4225297T (cg-RX-API-DMAC7.html)
TW (1) TW202228693A (cg-RX-API-DMAC7.html)
WO (1) WO2022074124A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202304965B (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202304911A (zh) * 2021-04-23 2023-02-01 大陸商南京明德新藥研發有限公司 吡啶醯胺類化合物
WO2023036285A1 (zh) * 2021-09-09 2023-03-16 南京奥利墨斯医药科技有限公司 一种杂芳环类化合物及其应用
US20230250428A1 (en) * 2022-02-07 2023-08-10 Alliance Of Cardiovascular Researchers Method and composition for early detection of malignancies
IL316019A (en) * 2022-04-07 2024-11-01 Astrazeneca Ab Combined treatment for cancer
CA3254948A1 (en) * 2022-04-07 2023-10-12 Astrazeneca Ab Polytherapy for the treatment of cancer
CN121464135A (zh) * 2023-07-07 2026-02-03 优领医药科技(香港)有限公司 含哌嗪并环类衍生物的晶型、其盐型、其制备方法及应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6648040B2 (ja) * 2014-05-28 2020-02-14 エーザイ・アール・アンド・ディー・マネジメント株式会社 がん治療のための併用療法としてのエリブリン及びポリ(adpリボース)ポリメラーゼ(parp)阻害剤の使用
TWI837403B (zh) * 2019-07-19 2024-04-01 瑞典商阿斯特捷利康公司 化學化合物

Similar Documents

Publication Publication Date Title
ES2576289T3 (es) Nanopartículas de paclitaxel y albúmina en combinación con bevacizumab contra el cáncer
Mjos et al. Metallodrugs in medicinal inorganic chemistry
Hartinger et al. KP1019, a new redox‐active anticancer agent–Preclinical development and results of a clinical phase I study in tumor patients
FI4225297T3 (fi) Yhdistelmälääkehoito syövän hoidossa
US20230398119A1 (en) Combination therapy involving diaryl macrocyclic compounds
CN109069500B (zh) 一种用于治疗胃癌的喹啉衍生物
JP2012515184A (ja) 大腸がんの治療方法
US9370535B2 (en) Method for treatment of advanced solid tumors
JP2003533485A5 (cg-RX-API-DMAC7.html)
JP6410795B2 (ja) カルボキシアミドトリアゾールオロテートを使用する、先の化学療法薬および標的薬物に対する獲得耐性を持つ癌を治療するための方法および組成物
JP2019501185A (ja) 食道癌を治療するためのキノリン誘導体の使用とその治療方法、医薬組成物及びキット
Higuchi et al. A phase I trial of definitive chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil (DCF-R) for advanced esophageal carcinoma: Kitasato digestive disease & oncology group trial (KDOG 0501)
ES2389809T3 (es) Terapias anticancerosas
CN110522753A (zh) 一种新型抗肿瘤药物组合物、制剂和应用
ES2299841T3 (es) Composiciones farmaceuticas que comprenden azd2171 y zd6126, y usos de los mismos.
JP2022542725A (ja) 化合物又はその薬学的に許容される塩、二量体又は三量体のがん治療用医薬品の調製における応用
Malviya et al. Advances in Metallodrug-driven Combination Therapy for Treatment of Cancer
CN105263499B (zh) 用于癌症治疗的ro5503781、卡培他滨和奥沙利铂的组合
US9114149B2 (en) [CU(thp)4]n[X]-n compounds for the treatment of a broad range of human solid tumors, including refractory tumors
KR20060130764A (ko) 병용 요법
JP2024520307A5 (cg-RX-API-DMAC7.html)
JP2007508331A (ja) オキソプラチン、その塩および誘導体を含む医薬組成物
CN106038571B (zh) 一种含小分子靶向药物吉非替尼的药物组合物及其在制备抗肿瘤药物中的应用
CN110787303A (zh) 一种Pt与巯基化合物的加合物Pt-SR、制备及应用
RU2026101563A (ru) Способы лечения пациентов с немелкоклеточным раком легких, имеющих аберрацию в гене egfr